Drug class
Cardiac myosin inhibitor; allosteric, reversible sarcomere modulator
Mechanism of action
Allosterically and reversibly inhibits cardiac myosin motor activity, reducing force generation at the cardiac sarcomere. This decreases myocardial contractility and left-ventricular outflow-tract obstruction in hypertrophic cardiomyopathy.
General use cases
- Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms under the US FDA indication; requires product-specific echocardiographic monitoring and risk controls
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
